LFMD
LifeMD, Inc.
$5.02
+2.66%
$233.1M
No data for this timeframe.
Vol
Market Cap$233.1M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders7 funds
Inst. Value$13.8M
Inst. Activity1 buys / 4 sells
Reddit Sentiment58° Warm
SEC Reports1
Press Releases3
Exchange Nasdaq·Sector Services-Offices & Clinics of Doctors of Medicine·Inc. DE·CIK 0000948320·Prev Close $4.89
Recent Activity
Jun 5, 2026
short_volume
Short Volume: LFMD — 66.2% short (0.4M / 0.6M)
Short: 388,383 | Exempt: 400 | TRF Vol: 586,713 | Short Ratio: 66.2% | Off-exchange volume (dark poo
Jun 1, 2026
Insider
Sripad Umesh sold 75,000 shares
Chief Technology Officer @ $0.00 ($0.00)
May 11, 2026
Insider
Kavthekar Atul sold 337,500 shares
Chief Financial Officer @ $0.00 ($0.00)
Apr 27, 2026
SEC
LifeMD announced it will report Q1 2026 earnings on May 6, 2026, after market close, followed by a conference call. No f
PRESS-RELEASE — Impact 3/10
Mar 31, 2026
Press
LifeMD launched a subscription program for Novo Nordisk's Wegovy® (semaglutide), offering patients up to $1,200 in annua
Impact 4/10
Mar 30, 2026
Insider
Pisano Christopher A sold 200,000 shares
Chief Marketing Officer @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — TRIM
326,205 shares ($1.1M)
Inst.
BANK OF AMERICA CORP — TRIM
44,238 shares ($150.9K)
Price Targets
$9.88
+104.9% upside
Strong Buy
Current $4.82
Low $8.00
Median $10.00
High $15.00
8 analysts
$8.00
$15.00
Analyst Ratings
3Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 4, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 16, 2026 | Mizuho | UPGRADE | Neutral → Outperform |
| Mar 12, 2026 | Freedom Broker | MAINTAIN | Buy → Buy |
| Mar 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.04 ▼ -400.0% | $-0.09 — $0.00 | -302% YoY | 2 |
| Next Q | $0.17 ▲ +126.7% | $0.11 — $0.23 | 304% YoY | 2 |
| Current FY | $0.14 ▼ -3.6% | $0.02 — $0.25 | -8% YoY | 2 |
| Next FY | $0.52 ▲ +15.7% | $0.48 — $0.55 | 281% YoY | 2 |
Latest Reports
NEUTRAL
PRESS-RELEASE
3/10
LifeMD announced it will report Q1 2026 earnings on May 6, 2026, after market close, followed by a conference call. No f
Apr 27, 2026
NEUTRAL
Press
4/10
LifeMD launched a subscription program for Novo Nordisk's Wegovy® (semaglutide), offering patients up to $1,200 in annua
Mar 31, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $6.9M | — |
| RENAISSANCE TECHNOLOGIES LLC | $5.1M | ADD |
| MORGAN STANLEY | $1.1M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $386.4K | NEW |
| BANK OF AMERICA CORP | $150.9K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Sripad Umesh | A | $0.00 |
| May 11, 2026 | Kavthekar Atul | A | $0.00 |
| Mar 30, 2026 | Pisano Christopher | A | $0.00 |
Reddit Sentiment
58°
Warm
Bearish
Neutral
Bullish
7 institutional holders with $13.8M total value (4,049,927 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net selling activity: 4 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,021,704 | $6.9M | 49.9% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,498,325 | $5.1M | 37.0% | ADD +50.4% |
| 3 | MORGAN STANLEY | 326,205 | $1.1M | 8.1% | TRIM -66.6% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 113,315 | $386.4K | 2.8% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 44,238 | $150.9K | 1.1% | TRIM -58.9% |
| 6 | WELLS FARGO & COMPANY/MN | 44,162 | $150.6K | 1.1% | ADD +71.4% |
| 7 | FMR LLC | 1,978 | $6.7K | 0.0% | NEAR_EXIT -90.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 975,757 | 326,205 | -66.6% | $1.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 107,741 | 44,238 | -58.9% | $150.9K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 25,766 | 44,162 | +71.4% | $150.6K | 2025-Q4 |
| FMR LLC | NEAR_EXIT | 19,705 | 1,978 | -90.0% | $6.7K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 207,528 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,086,200 | 1,633,825 | +50.4% | $11.1M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 1,593,282 | 975,757 | -38.8% | $6.6M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 450,527 | 207,528 | -53.9% | $1.4M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 20,401 | 25,766 | +26.3% | $175.0K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 746,020 | 1,593,282 | +113.6% | $21.7M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 486,100 | 1,086,200 | +123.5% | $14.8M | 2025-Q2 |
| UBS Group AG | DOUBLED | 77,887 | 937,331 | +1103.4% | $12.8M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 30,400 | 450,527 | +1382.0% | $6.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 26,879 | 112,659 | +319.1% | $1.5M | 2025-Q2 |
| FMR LLC | DOUBLED | 3,197 | 18,760 | +486.8% | $255.5K | 2025-Q2 |
| MORGAN STANLEY | ADD | 418,690 | 746,020 | +78.2% | $4.1M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 148,017 | 652,082 | +340.5% | $3.5M | 2025-Q1 |
| UBS Group AG | TRIM | 244,908 | 77,887 | -68.2% | $423.7K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 30,400 | — | $165.4K | 2025-Q1 |
| FMR LLC | ADD | 2,275 | 3,197 | +40.5% | $17.4K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 351,204 | 510,000 | +45.2% | $2.5M | 2024-Q4 |
| UBS Group AG | ADD | 158,123 | 244,908 | +54.9% | $1.2M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 231,072 | 148,017 | -35.9% | $732.7K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 12,941 | 18,732 | +44.7% | $92.7K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 626,494 | 338,651 | -45.9% | $1.8M | 2024-Q3 |
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Sripad Umesh | Chief Technology Officer | A | 75,000 | $0.00 | $0.00 |
| May 11, 2026 | Kavthekar Atul | Chief Financial Officer | A | 337,500 | $0.00 | $0.00 |
| Mar 30, 2026 | Pisano Christopher A | Chief Marketing Officer | A | 200,000 | $0.00 | $0.00 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 3.0/10.
NEUTRAL
4/10
LifeMD launched a subscription program for Novo Nordisk's Wegovy® (semaglutide), offering patients u
Mar 31, 2026
NEUTRAL
3/10
LifeMD announced a cash dividend of $0.5546875 per share for its Series A Preferred Stock. This is a
Mar 24, 2026
BULLISH
8/10
LifeMD reported strong full-year 2025 results with 25% revenue growth to $194.1 million and a 309% i
Mar 9, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 3 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$9.88 mean target
+104.9% upside
Strong Buy (1.00)
$8.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $4.82 |
| Target Low | $8.00 |
| Target Mean | $9.88 |
| Target Median | $10.00 |
| Target High | $15.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.04 | $-0.09 | $0.00 | -301.8% | -400.0% | 0↑ 1↓ | $0.0B | -21.0% | 2 |
| Next Q 2026-09-30 |
$0.17 | $0.11 | $0.23 | 304.1% | +126.7% | 0↑ 1↓ | $0.1B | -2.7% | 2 |
| Current FY 2026-12-31 |
$0.14 | $0.02 | $0.25 | -7.8% | -3.6% | 0↑ 1↓ | $0.2B | 14.4% | 2 |
| Next FY 2027-12-31 |
$0.52 | $0.48 | $0.55 | 281.5% | +15.7% | 0↑ 1↓ | $0.3B | 17.5% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.045 | |
| 7d ago | $-0.045 | |
| 30d ago | $0.015 | -0.060 |
| 60d ago | $0.015 | -0.060 |
| 90d ago | $0.120 | -0.165 |
4 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 4, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 16, 2026 | Mizuho | UPGRADE | Neutral | Outperform |
| Mar 12, 2026 | Freedom Broker | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | BTIG | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
58°
Warm
Bearish
Neutral
Bullish
2 mentions
1 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 9, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
$LFMD a telehealth company with a great outlook
▲ 5
💬 5
⚡ 0.0
On the Rebound — $MIGI, $HIT, $LFMD Bouncing
▲ 1
💬 0
⚡ 0.0
Jun 5, 2026
short_volume
Short Volume: LFMD — 66.2% short (0.4M / 0.6M)
Short: 388,383 | Exempt: 400 | TRF Vol: 586,713 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
other
LifeMD Appoints Umesh Sripad as Chief Technology Officer
Seasoned Technology Executive Brings More Than Two Decades of Large-Scale Digital Transformation Experience to Support LifeMD’s Next Phase of Growth <
May 15, 2026
other
LifeMD to Participate in Upcoming Investor Conferences
<p align="justify">NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=EG8bSW8HTyZm81S1YdUnuXNJA2HMrdmBY5
May 6, 2026
earnings
LifeMD Reports First Quarter 2026 Results
<p align="center"><strong><em>Conference</em></strong> <strong><em>call begins at 4:30 p.m. Eastern time today</em></strong></p>
May 6, 2026
short_volume
Short Volume: LFMD — 60.0% short (0.4M / 0.7M)
Short: 404,147 | Exempt: 604 | TRF Vol: 673,107 | Short Ratio: 60.0% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
LFMD Q1 2026 Earnings Scheduled — 2026-05-06
May 4, 2026
earnings_calendar
LFMD Q1 2026 Earnings Scheduled — 2026-05-04
Apr 27, 2026
earnings
LifeMD to Report First Quarter 2026 Financial Results on May 6
<p align="justify">NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=SQaj39YrNdAnRN4K7zAZiyWQvPqUlB1z
Apr 23, 2026
short_volume
Short Volume: LFMD — 59.7% short (0.4M / 0.6M)
Short: 372,337 | Exempt: 999 | TRF Vol: 623,636 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_volume
Short Volume: LFMD — 64.2% short (1.3M / 2.0M)
Short: 1,285,935 | Exempt: 33,942 | TRF Vol: 2,004,547 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
other
LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapi
Mar 31, 2026
contract
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD’s collaboration with Novo Nordisk <pre>Delivering up to $
Mar 24, 2026
dividend
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
<p align="justify">NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=771OWPRk8iZpS03ty8fZPQH4cYrUR1G1
Mar 11, 2026
short_interest
FTD: LFMD — 149,364 shares ($0.6M) failed to deliver
Settlement: 20260311, Price: $3.91, FTD Value: $584,013.24, LIFEMD INC
Mar 9, 2026
earnings
LifeMD Reports Fourth Quarter and Full Year 2025 Results
<p align="center"><strong><em>Conference</em></strong> <strong><em>call begins at 4:30 p.m. Eastern time today</em></strong></p>